Timing and expression of the angiopoietin-1-Tie-2 pathway in murine lung development and congenital diaphragmatic

Adrienne Grzenda1, John Shannon, Jason Fisher

  • 1Charles Edison Laboratory for Pediatric Surgery Research, Department of Surgery, Division of Pediatric Surgery, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.

Insights

Congenital diaphragmatic hernia (CDH) causes lung and pulmonary hypertension issues. This study shows Angiopoietin-1 (Ang-1) pathway alterations may drive pulmonary vasculopathy in CDH.

Area of Science:

  • Developmental biology
  • Cardiovascular research
  • Pediatric medicine

Background:

  • Congenital diaphragmatic hernia (CDH) is a common birth defect causing severe respiratory insufficiency.
  • Pulmonary hypertension is a critical comorbidity in CDH, linked to mortality, but its molecular basis is unclear.
  • Angiopoietin-1 (Ang-1) is vital for vascular development, but its role in CDH-associated pulmonary hypertension is unknown.

Purpose of the Study:

  • To investigate the role of the Angiopoietin-1 (Ang-1) pathway in the development of pulmonary hypertension in a murine model of congenital diaphragmatic hernia (CDH).

Main Methods:

  • Established a nitrofen and bisdiamine-induced murine model of CDH.
  • Analyzed tissue-level expression and localization patterns of Ang-1 during normal lung development.
  • Examined expression of Ang-1, its receptor Tie-2, and transcription factor Ets-1 in the CDH model.

Main Results:

  • Angiopoietin-1 (Ang-1) is crucial for normal murine lung development, with defined expression patterns.
  • The study identified altered expression of Ang-1, Tie-2, and Ets-1 in the CDH model.
  • These alterations suggest a role in the pulmonary vasculopathy observed in congenital diaphragmatic hernia.

Conclusions:

  • The Angiopoietin-1 (Ang-1) pathway is implicated in normal lung development.
  • Aberrant Ang-1 pathway signaling contributes to pulmonary vasculopathy in congenital diaphragmatic hernia (CDH).
  • Targeting the Ang-1 pathway may offer therapeutic strategies for CDH-related pulmonary hypertension.